Posted Dec. 10, 2012 at 7:15 a.m.
Cancer research
Image 1 of 2 · Next Image…
Research Triangle Park, N.C. — GlaxoSmithKline signs a research and development deal with the MD Anderson Cancer Center in Texas that will focus on using the body's immune system to fight cancer. The deal could be worth $335 million plus royalties.
GSK strikes $335M drug deal with Texas cancer center
Post a comment
Print this blog postE-mail blog post
Share
Cancer research
Image 1 of 2 · Next Image…
Research Triangle Park, N.C. — GlaxoSmithKline signs a research and development deal with the MD Anderson Cancer Center in Texas that will focus on using the body's immune system to fight cancer. The deal could be worth $335 million plus royalties.
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 WRAL Tech Wire. All rights reserved.Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy - Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows
- Titans of tech seek to excite UNC, Duke grads about a future beyond themselves
- Triangle politician tries to accelerate crowdfunding; bill passes first hurdle
- ChannelAdvisor seeks $80M, sets share target price for IPO